Comparative Pharmacology
Head-to-head clinical analysis: FAVLYXA versus VITRAVENE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAVLYXA versus VITRAVENE PRESERVATIVE FREE.
FAVLYXA vs VITRAVENE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acyclic nucleoside phosphonate prodrug that inhibits viral RNA-dependent RNA polymerase (RdRP) by competing with adenosine triphosphate (ATP). It incorporates into nascent viral RNA causing chain termination after incorporation of the first 1-2 nucleotides.
Antisense oligonucleotide that binds to mRNA of human cytomegalovirus (HCMV), inhibiting viral replication by blocking protein synthesis.
200 mg orally twice daily for 10 days.
Intravitreal injection: 330 mcg (0.05 mL of 6.6 mg/mL solution) every 2 weeks for 2 doses, then every 4 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 5-7 hours in patients with normal renal function; prolonged in renal impairment (up to 24 hours in severe impairment).
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10 hours.
Primarily renal excretion of unchanged drug (approx. 85%) with biliary/fecal elimination accounting for the remainder (approx. 15%).
Primarily renal excretion. Approximately 40% of the dose is excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Antiviral
Antiviral